120 related articles for article (PubMed ID: 9122868)
1. Dehydroepiandrosterone-sulfate inhibits pancreatic carcinoma cell proliferation in vitro and in vivo.
Melvin WS; Boros LG; Muscarella P; Brandes JL; Johnson JA; Fisher WE; Schirmer WJ; Ellison EC
Surgery; 1997 Apr; 121(4):392-7. PubMed ID: 9122868
[TBL] [Abstract][Full Text] [Related]
2. Oral dehydroepiandrosterone inhibits the growth of human pancreatic cancer in nude mice.
Muscarella P; Boros LG; Fisher WE; Rink C; Melvin WS
J Surg Res; 1998 Oct; 79(2):154-7. PubMed ID: 9758731
[TBL] [Abstract][Full Text] [Related]
3. Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorylation.
Abe M; Yamashita J; Ogawa M
Cancer; 2000 May; 88(9):2000-9. PubMed ID: 10813710
[TBL] [Abstract][Full Text] [Related]
4. Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells.
Kuramoto M; Yamashita J; Ogawa M
Cancer; 1995 Mar; 75(6):1263-72. PubMed ID: 7882277
[TBL] [Abstract][Full Text] [Related]
5. High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy.
Morris KT; Toth-Fejel S; Schmidt J; Fletcher WS; Pommier RF
Surgery; 2001 Dec; 130(6):947-53. PubMed ID: 11742322
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts.
Celinski SA; Fisher WE; Amaya F; Wu YQ; Yao Q; Youker KA; Li M
J Surg Res; 2003 Nov; 115(1):41-7. PubMed ID: 14572771
[TBL] [Abstract][Full Text] [Related]
7. The effect of high dehydroepiandrosterone sulfate levels on tamoxifen blockade and breast cancer progression.
Calhoun K; Pommier R; Cheek J; Fletcher W; Toth-Fejel S
Am J Surg; 2003 May; 185(5):411-5. PubMed ID: 12727558
[TBL] [Abstract][Full Text] [Related]
8. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation.
Boros LG; Puigjaner J; Cascante M; Lee WN; Brandes JL; Bassilian S; Yusuf FI; Williams RD; Muscarella P; Melvin WS; Schirmer WJ
Cancer Res; 1997 Oct; 57(19):4242-8. PubMed ID: 9331084
[TBL] [Abstract][Full Text] [Related]
9. A quinolinone derivative, vesnarinone (OPC-8212), significantly inhibits the in vitro and in vivo growth of human pancreatic cancer cell lines.
Nio Y; Ohmori H; Minari Y; Hirahara N; Sasaki S; Takamura M; Tamura K
Anticancer Drugs; 1997 Aug; 8(7):686-95. PubMed ID: 9311445
[TBL] [Abstract][Full Text] [Related]
10. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
[TBL] [Abstract][Full Text] [Related]
11. Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer.
Bhargava S; Hotz B; Hines OJ; Reber HA; Buhr HJ; Hotz HG
J Gastrointest Surg; 2007 Feb; 11(2):171-8. PubMed ID: 17390169
[TBL] [Abstract][Full Text] [Related]
12. Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.
Vallera DA; Stish BJ; Shu Y; Chen H; Saluja A; Buchsbaum DJ; Vickers SM
Gut; 2008 May; 57(5):634-41. PubMed ID: 18222985
[TBL] [Abstract][Full Text] [Related]
13. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
Miknyoczki SJ; Chang H; Klein-Szanto A; Dionne CA; Ruggeri BA
Clin Cancer Res; 1999 Aug; 5(8):2205-12. PubMed ID: 10473107
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of endothelin receptor A as an anti-angiogenic and anti-proliferative strategy for human pancreatic cancer.
Bhargava S; Stummeyer T; Hotz B; Hines OJ; Reber HA; Buhr HJ; Hotz HG
J Gastrointest Surg; 2005; 9(5):703-9. PubMed ID: 15862267
[TBL] [Abstract][Full Text] [Related]
15. Dehydroepiandrosterone and related steroids alter 3T3-L1 preadipocyte proliferation and differentiation.
Lea-Currie YR; Monroe D; Mcintosh MK
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol; 1999 May; 123(1):17-25. PubMed ID: 10390052
[TBL] [Abstract][Full Text] [Related]
16. Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP.
Qin Y; Ertl T; Cai RZ; Horvàth JE; Groot K; Schally AV
Int J Cancer; 1995 Oct; 63(2):257-62. PubMed ID: 7591214
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral chemotherapy with a sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts.
Smith JP; Stock E; Orenberg EK; Yu NY; Kanekal S; Brown DM
Anticancer Drugs; 1995 Dec; 6(6):717-26. PubMed ID: 8845483
[TBL] [Abstract][Full Text] [Related]
18. Effect of dehydroepiandrosterone and its sulfate metabolite on neuronal cell viability in culture.
Gil-ad I; Shtaif B; Eshet R; Maayan R; Rehavi M; Weizman A
Isr Med Assoc J; 2001 Sep; 3(9):639-43. PubMed ID: 11574977
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995.
Upp JR; Olson D; Poston GJ; Alexander RW; Townsend CM; Thompson JC
Am J Surg; 1988 Jan; 155(1):29-35. PubMed ID: 2893555
[TBL] [Abstract][Full Text] [Related]
20. [Molecular mechanisms of DHEA and DHEAs on apoptosis and cell cycle arrest via Akt pathway in hepatoma cell lines].
Jiang YF; Zhao PW; Tan Y; Liu LH; Li MH; Matsuzaki Y; Niu JQ
Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):441-4. PubMed ID: 17594810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
